Pharmacokinetics of ceftiofur sodium in Peekapoo dogs following a single intravenous and subcutaneous injection.

Abstract

The present study aimed to determine the pharmacokinetic profiles of ceftiofur (as measured by ceftiofur and its active metabolites concentrations) in a small-size dog breed, Peekapoo, following a single intravenous or subcutaneous injection of ceftiofur sodium. The study population comprised of five clinically healthy Peekapoo dogs with an average body weight (BW) of 3.4kg. Each dog received either intravenous or subcutaneous injection, both at 5mg/kg BW (calculated as pure ceftiofur). Plasma samples were collected at different time points after the administration. Ceftiofur and its active metabolites were extracted from plasma samples, derivatized, and further quantified by high-performance liquid chromatography. The concentrations versus time data were subjected to noncompartmental analysis to obtain the pharmacokinetic parameters. The terminal half-life (t1/2 λz ) was calculated as 7.40±0.79 and 7.91±1.53hr following intravenous and subcutaneous injections, respectively. After intravenous treatment, the total body clearance (Cl) and volume of distribution at steady-state (VSS ) were determined as 39.91±4.04mlhr-1 kg-1 and 345.71±28.66ml/kg, respectively. After subcutaneous injection, the peak concentration (Cmax ; 10.50±0.22μg/ml) was observed at 3.2±1.1hr, and the absorption half-life (t1/2 ka ) and absolute bioavailability (F) were calculated as 0.74±0.23hr and 91.70%±7.34%, respectively. The pharmacokinetic profiles of ceftiofur and its related metabolites demonstrated their quick and excellent absorption after subcutaneous administration, in addition to poor distribution and slow elimination in Peekapoo dogs. Based on the time of concentration above minimum inhibitory concentration (T>MIC) values calculated here, an intravenous or subcutaneous dose at 5mg/kg of ceftiofur sodium once every 12hr is predicted to be effective for treating canine bacteria with a MIC value of ≤4.0μg/ml.